This trial will evaluate the safety and effectiveness of the ACURATE Transfemoral Aortic Valve System for transcatheter aortic valve replacement (TAVR) in subjects with severe native aortic stenosis who are indicated for TAVR.
1 Primary · 0 Secondary · Reporting Duration: Participants will be followed for the duration of the trial, through 10 years.
Active Control
Experimental Treatment
1720 Total Participants · 4 Treatment Groups
Primary Treatment: ACURATE neo2™ Transfemoral TAVR System · No Placebo Group · N/A
Age Any Age · All Participants · 8 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: